by Mark Chiang

马克·蒋

Share To

分享到

Akeso, Inc. has initiated its global Phase II registrational trial for cadonilimab, marking a significant step in the evaluation of this investigational therapy for patients with PD-1 treatment-resistant hepatocellular carcinoma (HCC). The company confirmed that the first patient has been dosed in the multicenter, randomized study known as COMPASSION-36/AK104-225.

康方生物已经启动了其卡度尼利单抗的全球II期注册试验，这标志着在评估这种研究性疗法对于PD-1治疗耐药的肝细胞癌（HCC）患者方面迈出了重要一步。公司确认，在名为COMPASSION-36/AK104-225的多中心、随机研究中，首位患者已经接受了给药。

This trial aims to assess the safety and efficacy of cadonilimab, a dual immune checkpoint inhibitor targeting PD-1 and CTLA-4..

本试验旨在评估针对PD-1和CTLA-4的双重免疫检查点抑制剂卡多尼利单抗的安全性和有效性。

The study is designed to enroll participants across multiple international sites and will focus on patients who have not responded to prior PD-1-based treatments for HCC. Cadonilimab combines two mechanisms of action by simultaneously inhibiting PD-1 and CTLA-4 pathways, which are critical targets in cancer immunotherapy.

该研究设计为在多个国际地点招募参与者，并将专注于对先前基于PD-1的肝细胞癌治疗无反应的患者。Cadonilimab通过同时抑制PD-1和CTLA-4通路结合了两种作用机制，这是癌症免疫治疗中的关键靶点。

Akeso’s announcement highlights its ongoing efforts to address unmet medical needs in advanced liver cancer through innovative therapeutic approaches. Further updates on the trial’s progress are expected as enrollment continues globally..

康方生物的公告强调了其通过创新疗法持续应对晚期肝癌未满足医疗需求的努力。随着全球范围内的患者招募持续进行，预计将进一步更新试验进展。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: September 15, 2025

日期：2025年9月15日

Related posts:

相关文章：

Generic Drug Developers Face Compliance Challenges Including ANDA Submissions.

通用药物开发者面临包括ANDA提交在内的合规挑战。

PLUSS Advanced Technologies and Ecodome Logistics Partner to Reduce Vaccine Wastage and Carbon Emissions in India

PLUSS先进技术和Ecodome物流合作，减少印度的疫苗浪费和碳排放

Scott Tillman Discusses How Uncertainty Drives Supply Chain Investments in Flexibility and Responsiveness

斯科特·蒂尔曼讨论不确定性如何推动供应链在灵活性和响应能力方面的投资

Pharmacist Dr. Alyssa Modic Highlights Need for Evidence-Based Advocacy Amid Evolving COVID-19 Vaccine Guidance

药剂师阿丽莎·莫迪奇博士强调在不断演变的新冠疫苗指南中需要基于证据的倡导。

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·蒋

Related Post

相关内容

News Flash

新闻快讯

MGI Tech Unveils DNBSEQ-T7+ High-Throughput Sequencer for Large-Scale Genomic Projects

华大智造推出用于大规模基因组项目的DNBSEQ-T7+高通量测序仪

2025-09-15

2025年9月15日